Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Autoimmune Disorders

Free Subscription 01.12.2025 3 BMC Neurol 2 J Immunol 4 J Neurol 3 Neurology 1 PLoS Med 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. RIVERA SANCHEZ M, Gallego de Largy CC, Martin Arroyo J, Polanco Fernandez M, et al
   An atypical case of overlapped anti-NMDA-R and anti-GFAP encephalitis secondary to a teratoma of the fallopian tube: a case report.
   BMC Neurol. 2025;25:488.
   PubMed         Abstract available
   
   
2. NAIR P, Srikumar B, Sunil MS, Iype T, et al
   Utility of transorbital ultrasound to assess disability and axonal loss in multiple sclerosis.
   BMC Neurol. 2025;25:482.
   PubMed         Abstract available
   
   
3. CHEN Y, Zhou G, Dai K, Tan Z, et al
   Overlapping autoimmune encephalitis with tripartite autoantibody positivity (NMDAR, GFAP, mGluR5) associated with papillary thyroid carcinoma: a case report.
   BMC Neurol. 2025;25:480.
   PubMed         Abstract available
   
   

   
   J Immunol

4. RACINE JJ, Dwyer JR, Chapman HD, Bell A, et al
   Direct-in-NOD genetic ablation of Bcl3 leads to complete type 1 diabetes protection.
   J Immunol. 2025 Aug 12:vkaf189. doi: 10.1093.
   PubMed         Abstract available
   
   
5. YU R, Kim S, Li S, Yang W, et al
   Intronic miR-342 is a key regulator of cellular glycolysis in Foxp3+ regulatory CD4 T cells.
   J Immunol. 2025;214:2976-2986.
   PubMed         Abstract available
   
   

   
   J Neurol

6. KLEINSCHNITZ C, Skripuletz T, Pfeuffer S, Pawlitzki M, et al
   Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.
   J Neurol. 2025;272:788.
   PubMed         Abstract available
   
   
7. PIERVINCENZI C, Ojha A, Tommasin S, Satriano F, et al
   Functional connectivity changes are associated with disability progression in multiple sclerosis: a longitudinal fMRI study.
   J Neurol. 2025;272:787.
   PubMed         Abstract available
   
   
8. ARSLAN D, Colpak AI, Yardimci GK, Bulut EG, et al
   Neurological involvement in IgG4-related disease: focus on neuro-ophthalmologic features.
   J Neurol. 2025;272:785.
   PubMed         Abstract available
   
   
9. BALSHI A, Dempsey JP, Kumbar S, Manning N, et al
   Motherhood and diagnostic delay among women with multiple sclerosis.
   J Neurol. 2025;272:784.
   PubMed         Abstract available
   
   

   
   Neurology

10. DAMULINA A, Opriessnig P, Pirpamer L, Demjaha R, et al
    Association of CSF Kappa-Free Light Chains With Cortical and Periventricular Brain Damage in Multiple Sclerosis.
    Neurology. 2025;105:e214433.
    PubMed         Abstract available
    
    
11. TRENTADUE T, Martinez Sosa S, Itoh CY, Modi T, et al
    Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.
    Neurology. 2025;105:e214429.
    PubMed         Abstract available
    
    
12. DE MEO E, Addazio I, Portaccio E, Bonacchi R, et al
    Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.
    Neurology. 2025;105:e214408.
    PubMed         Abstract available
    
    

    
    PLoS Med

13. SYDNEY GI, Perdigoto AL, Herold KC
    Towards insulin independence in type 1 diabetes: Prospects for prevention and cure.
    PLoS Med. 2025;22:e1004813.
    PubMed         Abstract available
    
    

    
    PLoS One

14. CHERO-SANDOVAL L, Higuera-Gomez A, de Cuevillas B, Castejon R, et al
    Body mass index distinctly modulates the associations between Alistipes and CRP/IL-6 in metabolic and lupus inflammatory features.
    PLoS One. 2025;20:e0335452.
    PubMed         Abstract available
    
    
15. FISHER SS, Lindaas A, Muthuri SG, Lloyd PC, et al
    Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
    PLoS One. 2025;20:e0333704.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.